| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-09 | 7480.44万 | 217.74万 | 3.00% | | 2026-02-06 | 7262.70万 | -36.36万 | -0.50% | | 2026-02-05 | 7299.06万 | -70.50万 | -0.96% | | 2026-02-04 | 7369.56万 | -84.60万 | -1.13% | | 2026-02-03 | 7454.16万 | 304.38万 | 4.26% | 证券之星消息，2月9日南向资金增持217.74万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持330.66万股。近20个交易日中，获南向资金增持的有11天，累计净增持716.04 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7480.44万股，占公司已发行普通股的5.66%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及 ...

Group 1 - The core viewpoint of the news is that Puri Eye Hospital has shown a slight increase in stock price and has low financing and margin trading balances, indicating a cautious market sentiment towards the company [1] - On January 26, Puri Eye Hospital's stock rose by 0.66%, with a trading volume of 66.66 million yuan. The financing buy amount was 6.065 million yuan, while the financing repayment was 7.893 million yuan, resulting in a net financing outflow of 1.828 million yuan [1] - As of January 26, the total financing and margin trading balance for Puri Eye Hospital was 70.3743 million yuan, with the financing balance accounting for 1.33% of the circulating market value, which is below the 10th percentile level over the past year [1] Group 2 - As of September 30, Puri Eye Hospital had 10,400 shareholders, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - For the period from January to September 2025, Puri Eye Hospital achieved an operating income of 2.201 billion yuan, representing a year-on-year growth of 2.99%, and a net profit attributable to shareholders of 16.3491 million yuan, up 3.21% year-on-year [2] - Since its A-share listing, Puri Eye Hospital has distributed a total of 74.5074 million yuan in dividends [3]

Group 1 - Core viewpoint: Puri Eye Hospital has seen a continuous increase in stock price, with a 5-day cumulative increase of 5.84% as of January 14, reaching a price of 34.26 yuan per share and a total market capitalization of 5.126 billion yuan [1] - Company overview: Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022. The company provides comprehensive medical services for eye diseases, including diagnosis, treatment, healthcare, and optical services [1] - Revenue composition: The main business revenue is derived from refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), vision projects (13.03%), and other services (1.18%) [1] Group 2 - Shareholder information: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) is among the top ten circulating shareholders of Puri Eye Hospital, having reduced its holdings by 192,500 shares in the third quarter, now holding 2.4 million shares, which is 1.69% of the circulating shares [2] - Fund performance: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has achieved a year-to-date return of 9.61% and a one-year return of 26.99%, ranking 782 out of 8,838 and 4,859 out of 8,089 respectively [2] - Fund manager details: The fund manager, Wan Minyuan, has a tenure of 9 years and 144 days, with a total fund asset size of 5.957 billion yuan and a best return of 149.74% during his tenure [2]

Core Viewpoint - On November 7, 2023, Puri Eye Hospital's stock decreased by 0.22%, with a trading volume of 27.86 million yuan, indicating a relatively stable market performance despite minor fluctuations [1] Financing Summary - On November 7, Puri Eye Hospital had a financing buy-in amount of 3.47 million yuan and a financing repayment of 3.18 million yuan, resulting in a net financing buy-in of 0.28 million yuan [1] - The total financing and securities balance as of November 7 was 72.47 million yuan, with the financing balance at 71.80 million yuan, accounting for 1.30% of the circulating market value, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The securities lending data showed a repayment of 100 shares with no shares sold, and a remaining securities lending balance of 67.53 million yuan, which is above the 60th percentile level over the past year, indicating a relatively high level of securities lending [1] Business Performance - As of September 30, 2023, Puri Eye Hospital reported a total revenue of 2.20 billion yuan for the first nine months of 2023, reflecting a year-on-year growth of 2.99% [2] - The net profit attributable to the parent company for the same period was 16.35 million yuan, showing a year-on-year increase of 3.21% [2] - The company has distributed a total of 74.51 million yuan in dividends since its A-share listing [3] Shareholder Information - As of September 30, 2023, the number of shareholders for Puri Eye Hospital was 10,400, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund held 2.40 million shares, a decrease of 192,500 shares from the previous period, while the Yuanxin Yongfeng Medical Health A Fund entered the top ten with 2.02 million shares [3]

Core Insights - On October 10, 2023, Puri Eye Hospital's stock rose by 0.87%, with a trading volume of 50.26 million yuan [1] - The company reported a financing buy-in of 3.29 million yuan and a net financing buy of 135,200 yuan on the same day [1] - As of October 10, the total margin balance for Puri Eye Hospital was 70.78 million yuan, indicating a low financing balance compared to the past year [1] Financing and Margin Data - On October 10, the financing buy-in was 3.29 million yuan, while the financing repayment was 3.15 million yuan, resulting in a net buy of 135,200 yuan [1] - The current financing balance stands at 70.13 million yuan, which is 1.27% of the circulating market value, below the 10% percentile level over the past year [1] - The margin trading data shows that 200 shares were repaid, and 1,700 shares were sold short, with a short selling amount of 63,000 yuan [1] Company Overview - Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022 [1] - The company provides comprehensive eye care services, including diagnosis, treatment, and optical services [1] - The revenue composition includes refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), and optical projects (13.03%) [1] Shareholder and Financial Performance - As of June 30, 2023, the number of shareholders increased by 6.24% to 10,600, while the average circulating shares per person decreased by 5.87% to 6,647 shares [2] - For the first half of 2023, Puri Eye Hospital achieved a revenue of 1.46 billion yuan, a year-on-year increase of 2.74%, but the net profit attributable to shareholders decreased by 66.12% to 14.67 million yuan [2] - Cumulatively, the company has distributed 74.51 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The financial performance of Purui Eye Hospital Group shows mixed results, with a slight increase in revenue but a significant decrease in net profit, indicating potential challenges in profitability despite stable revenue growth [2][3]. Group 1: Financial Performance - As of June 30, 2025, Purui Eye Hospital achieved a revenue of 1.459 billion yuan, representing a year-on-year growth of 2.74% [2]. - The net profit attributable to shareholders for the same period was 14.67 million yuan, reflecting a substantial decline of 66.12% compared to the previous year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to 74.51 million yuan [3]. Group 2: Shareholder and Market Activity - As of August 28, 2023, the total number of shareholders for Purui Eye Hospital reached 10,600, an increase of 6.24% from the previous period [2]. - The average number of circulating shares per shareholder is 6,647, which is a decrease of 5.87% from the previous period [2]. - On August 28, 2023, the financing balance for Purui Eye Hospital was 94.61 million yuan, accounting for 1.47% of its market capitalization, indicating a low financing level compared to the past year [1]. Group 3: Institutional Holdings - As of June 30, 2025, the third-largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.5925 million shares, an increase of 692,400 shares from the previous period [3]. - Yuanxin Yongfeng Ju You A is a new entrant among the top ten circulating shareholders, holding 1.7668 million shares [3]. - The tenth-largest circulating shareholder, ICBC Medical Care Stock, reduced its holdings by 90,000 shares compared to the previous period [3].